For grade 4 neutropenia persisting for >7 days, a dose delay >2 weeks, grade 4 thrombocytopenia or an episode of thrombocytopenic bleeding, the dose was reduced by 20 mg m or one dose level.
The addition of pharmacological treatment (LMWH) is even more protective in terms of reduction of VTE, with a modest increase in the frequency of major bleeding: the dose should not exceed 4,000 IU/day, and the administration should begin on the day after surgery.
Patients in the AT III group who received concomitant heparin had a significantly higher incidence of bleeding events, and outcome worsened as the dose of heparin increased.
Testing for an association between the dose of ALT-836 and bleeding was performed using a χ2 test for trend.
Current practice is to increase the dose of ethinylestradiol in case of disruptions in bleeding patterns.
For treatment of a bleeding episode, the dose was based upon subject's PK profile, WFH guidelines and local standard of care, with a minimum dose of 25 IU kg−1 rIX-FP.
Although the dose of aspirin was not randomly assigned, the finding of increased bleeding with doses >162 mg/d is noteworthy.
A dose of 150 mg twice daily is recommended unless the patients are ≥80 years, or with an increased risk of bleeding where a dose of 110 mg twice daily is preferred/should be considered.
If clotting was noticed (by vision) in the system or if there was a bleeding tendency, the dose was changed in steps of 500 units, according to the manufacturer's recommendations.
Development of complications has been associated to some risk factors such as background of having suffered peptic ulcer or gastrointestinal tract bleeding, age, dose and type of NSAID used, the simultaneous use of two NSAIDs or a NSAID with corticosteroids or with anticoagulants and having a serious underlying disease.
